ストックスクリーナーアプリを入手
4.19
4.75%
0.19
前日終値:
$4.00
開ける：
$4.06
24時間の取引高:
91,881
Relative Volume:
2.54
時価総額：
$138.25M
収益：
$24.99M
当期純損益:
$-65.24M
株価収益率:
-1.8622
EPS:
-2.25
ネットキャッシュフロー:
$-21.27M
1週間 パフォーマンス:
-4.34%
1か月 パフォーマンス:
+26.59%
6か月 パフォーマンス:
+28.92%
1年 パフォーマンス:
+139.43%
1日の値動き範囲:
$4.06
$4.77
1週間の範囲:
$3.945
$4.77
52週間の値動き範囲:
$1.635
$5.24
Elutia Inc Stock (ELUT) Company Profile
ELUT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ELUT
Elutia Inc
|
4.19 | 138.25M | 24.99M | -65.24M | -21.27M | -2.25 |
|
ABT
Abbott Laboratories
|
118.95 | 208.18B | 41.22B | 5.77B | 6.49B | 2.94 |
|
SYK
Stryker Corp
|
388.14 | 148.70B | 21.97B | 3.59B | 3.21B | 6.74 |
|
BSX
Boston Scientific Corp
|
90.75 | 133.32B | 15.91B | 1.79B | 1.89B | 0.82 |
|
MDT
Medtronic Plc
|
86.27 | 111.27B | 33.00B | 4.29B | 5.50B | 2.71 |
|
EW
Edwards Lifesciences Corp
|
72.07 | 42.66B | 6.60B | 4.16B | 490.10M | 2.34 |
Elutia Inc Stock (ELUT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-11-02 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-11-02 | 開始されました | Cowen | Outperform |
| 2020-11-02 | 開始されました | Piper Sandler | Overweight |
| 2020-11-02 | 開始されました | Truist | Buy |
Elutia Inc (ELUT) 最新ニュース
ELUTElutia Inc. Latest Stock News & Market Updates - StockTitan
Elutia Inc. (NASDAQ:ELUT) Held Back By Insufficient Growth Even After Shares Climb 26% - Simply Wall St
Elutia Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Elutia Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Cantor Fitzgerald Reaffirms Overweight Rating for Elutia (NASDAQ:ELUT) - Defense World
Elutia's (ELUT) "Overweight" Rating Reaffirmed at Cantor Fitzgerald - MarketBeat
Elutia Inc (ELUT) Q3 2024 Earnings Call Highlights: Strategic Gr - GuruFocus.com
Elutia Inc (ELUT) Q3 2024 Earnings Call Highlights: Strategic Growth Amid Revenue Challenges By GuruFocus - Investing.com Canada
Elutia Inc. (ELUT) Quarterly 10-Q Report - Quartzy
Elutia Inc. Reports Strong Q3 Results, Prepares for Major Product Launch - TipRanks
Elutia Inc (ELUT) Q3 2024 Earnings: EPS of $0.03 Beats Estimates, Revenue of $5.92M Misses Expectations - GuruFocus.com
Elutia earnings beat by $0.11, revenue fell short of estimates - Investing.com UK
Elutia Announces Strong Third Quarter Results, Accelerating Toward Full Launch of EluPro® Antibiotic-Eluting BioEnvelope in 2025 - The Manila Times
Elutia to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum - The Manila Times
What To Expect From Elutia Inc (ELUT) Q3 2024 Earnings - GuruFocus.com
Elutia (ELUT) to Release Earnings on Thursday - Defense World
Elutia (ELUT) Set to Announce Earnings on Thursday - MarketBeat
Short Interest in Elutia Inc. (NASDAQ:ELUT) Rises By 7.4% - MarketBeat
Elutia to Report Third Quarter 2024 Financial Results on Thursday, November 14, 2024 - The Manila Times
Elutia to Present at the LD Micro Main Event XVII Conference on Wednesday, October 30 - The Manila Times
Individual investors among Elutia Inc.'s (NASDAQ:ELUT) largest stockholders and were hit after last week's 10% price drop - Simply Wall St
Contaminated donor tissue gave Georgia patient tuberculosis, lawsuit says - The Atlanta Journal Constitution
SILVERARC CAPITAL MANAGEMENT, LLC Acquires Shares in Elutia Inc - GuruFocus.com
Preclinical Data Show Efficacy Of Elutia's Antibiotic-Eluting BioEnvelope - MPO-mag
Preclinical Data Show Efficacy of Elutia’s Antibiotic-Eluting BioEnvelope - MPO-mag
Elutia (NASDAQ:ELUT) vs. Curis (NASDAQ:CRIS) Head to Head Comparison - Defense World
Nantahala Capital Management LLC Grows Stock Position in Elutia Inc. (NASDAQ:ELUT) - Defense World
Nantahala Capital Management LLC Purchases 145,697 Shares of Elutia Inc. (NASDAQ:ELUT) - MarketBeat
Short Interest in Elutia Inc. (NASDAQ:ELUT) Declines By 30.1% - MarketBeat
Elutia Inc. (NASDAQ:ELUT) Sees Large Decrease in Short Interest - Defense World
Elutia Announces New Peer Reviewed Publication Highlighting the Robustness of EluPro™, Company’s Antibiotic-Eluting BioEnvelope for Implantable Devices - StockTitan
Short Interest in Elutia Inc. (NASDAQ:ELUT) Decreases By 10.9% - MarketBeat
Elutia Announces First Patient Implant of EluPro™, the World’s First Drug-Eluting BioEnvelope for Cardiac Pacemakers and Neurostimulators - HMP Global Learning Network
Elutia announces first patient implant of EluPro, the world’s first drug-eluting bioenvelope for cardiac pacemakers and neurostimulators - Cardiovascular Business
AIGH Capital Management LLC Increases Position in Elutia Inc. (NASDAQ:ELUT) - MarketBeat
Cantor Fitzgerald Reiterates “Overweight” Rating for Elutia (NASDAQ:ELUT) - Defense World
Elutia Celebrates First Year - ForexTV.com
Elutia (NASDAQ:ELUT) Receives Overweight Rating from Cantor Fitzgerald - MarketBeat
Elutia Announces First Patient Implant of EluPro™, the - GlobeNewswire
Elutia to Participate in Upcoming Investor Conferences - ForexTV.com
Ryan Marques Joins Elutia As VP Of Operations - MPO-mag
Short Interest in Elutia Inc. (NASDAQ:ELUT) Expands By 468.3% - Defense World
Ryan Marques Joins Elutia as VP of Operations - MPO-mag
Elutia Inc. (NASDAQ:ELUT) Short Interest Update - MarketBeat
Spine Implant Caused Patient's TB, Suit Says - Law360
ELUT (Elutia) Financial Strength : 2 (As of Jun. 2024) - GuruFocus.com
ELUT (Elutia) Cash from Discontinued Operating Activities : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
Elutia Inc. (ELUT) Q2 2024 Earnings Call Transcript - Seeking Alpha
Elutia (NASDAQ:ELUT) Price Target Cut to $10.00 - MarketBeat
Elutia Wins FDA Clearance Of Its Antibiotic-Eluting BioEnvelope - MPO-mag
Elutia Inc (ELUT) 財務データ
収益
当期純利益
現金流量
EPS
0.65%
大文字化:
|
ボリューム (24 時間):